A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Exclusion Criteria

• •1. Subjects with known HER2-positive gastric cancer/adenocarcinoma of the gastroesophageal junction
• •2. Subjects have participated in any other clinical trial within 28 days prior to 1st dosing of investigational medicinal product (IMP).
• •3. Subjects with anti-tumor treatment within 21 days prior to 1st dosing of IMP.
• •4. Previous immunotherapy and grade ≥3 irAE or grade ≥2 immune-related myocarditis. (for cohorts treated with combination PD-1).
• •5. Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
• •6. Present peripheral sensory or motor neuropathy ≥ grade 2.
• •7. Subjects with uncontrolled pain.
• •8. Subjects with symptomatic/active central nervous system(CNS)metastases.
• •9. Subject who have uncontrollable third space effusion.
• •10. Subjects with known hypersensitivity to antibody therapy.
• •11. Subjects have treated with the same target.
• •12. Subjects have received Strong inhibitor/strong inducer of CYP3A4 within 14 days prior to first dose.
• •13. Use of any live vaccines within 28 days prior to 1st dosing of IMP.
• •14. Subjects with current or previous interstitial lung diseases or pneumonia requiring oral or intravenous glucocorticoids for adjuvant therapy.
• •15. Subjects on anticoagulants, such as heparin and vitamin K antagonists.
• •16. Clinically uncontrollable persistent recurrent vomiting.
• •17. Uncontrollable/severe gastrointestinal bleeding, ulceration or diarrhea within 28 days prior to first dose of IMP.
• •18. Subjects who received major surgery or interventional treatment within28 days prior to the first dosing of IMP.
• •19. Subjects who have other cancers, other than the one treated in this trial, within 2 years prior to screening.
• •20. Subjects who have severe cardiovascular disease.
• •21. Subjects who have uncontrolled or severe illness.
• •22. Subjects who take systemic corticosteroids (\> 10 mg daily prednisone equivalents) or other systemic immunosuppressive medications within 2 weeks prior to the first dosing of IMP.
• •23. Subjects with a known history of autoimmune diseases.
• •24. Subjects who have a history of immunodeficiency disease.
• •25. Subjects with HIV infection, active HBV or HCV infection.
• •26. Child-bearing potential female who have positive results in pregnancy test within 7 days before the first dose or are lactating.
• •27. Subject who have a known psychiatric diseases or disorders that may affect compliance with the trial.